Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Daily volatility informs risk tolerance and timing decisions. This overview highlights why investors should monitor volatility and adjust strategies.
28,131 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Gartner CEO Gene Hall tells investors the benefits from recent product and engagement upgrades will appear gradually ...
A leaked document outlines a SpaceX strategy to move AI compute to orbit, potentially reshaping investment bets acros...
The 2026 IPO boom is broadening beyond AI megadeals as mid-cap and overlooked sectors attract new capital. A busy sec...
Hess Midstream signals a major shift from expansion to cash returns, projecting $850-$900 million in adjusted free ca...
OpenAI leads the 2026 IPO chatter, with Stripe and Consensys jockeying for position as investors weigh odds, valuatio...
Meta's AI model projects a substantial rally for gold and silver by end-2026, framing both as twin bets on a shared m...
TJX shattered a retail milestone by exceeding $60 billion in annual revenue for the first time, signaling enduring st...
As Uber morphs into a multi-vertical platform, the real question for investors is how quickly it can translate growth...
The Virtus InfraCap U.S. Preferred Stock ETF trades near $21 with a 9.9% forward yield built on leverage and high-cou...
Both ServiceNow and Salesforce fell roughly 5% on the latest trading session as AI licensing concerns rattled investo...
A top research firm issues the highest conviction call realty on Realty Income, setting a bold price target as the RE...